Docetaxel in the Adjuvant Setting

Publisher： Karger

E-ISSN： 2296-5262|23|6|10-12

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.23, Iss.6, 2004-11, pp. : 10-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Trastuzumab in the adjuvant setting: a practical review

By Rossi Valentina   Redana Stefania   Milani Andrea   Geuna Elena   Valabrega Giorgio   Aglietta Massimo   Montemurro Filippo  

Therapy, Vol. 8, Iss. 2, 2011-03 ,pp. : 161-177

Future Medicine

Access to resources Recommend Favorite

Moving Forward: Herceptin® in the Adjuvant Setting

By  

Oncology, Vol. 63, Iss. 1, 2002-11 ,pp. : 57-63

Karger

Access to resources Recommend Favorite

Risk-Adapted Chemotherapy in the Adjuvant Setting of Breast Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-07 ,pp. : 200-201

Karger

Access to resources Recommend Favorite

Gynecological Cancers: A Challenge of Individualized Therapy in the Adjuvant and Palliative Setting

By  

Oncology Research and Treatment, Vol. 26, Iss. 5, 2003-11 ,pp. : 428-

Karger

Access to resources Recommend Favorite

Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer

By Martin Miguel  

Women's Health, Vol. 2, Iss. 4, 2006-07 ,pp. : 527-537

Future Medicine

Access to resources Recommend Favorite